Research on Solvonis Therapeutics Plc (SVNS:LON) from Turner Pope Investments
Solvonis Therapeutics plc has successfully raised £1.3 million through a placing of new ordinary shares at 0.12p per share, with the proceeds intended to advance key clinical and regulatory milestones for its central nervous system disorder therapeutics. The funds will support the assessment of international sites for the SVN-001 Phase 3 study, the advancement of SVN-002 towards an Investigational New Drug submission and Phase 2b readiness in the United States, and the progression of SVN-015 alongside the US National Institute on Drug Abuse. Turner Pope Investments has been appointed as the Company's corporate broker.
View Full Research

